No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Sunday, October 5, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Market Analysis

1 Stock to Buy, 1 Stock to Sell This Week: Meta Platforms, Pfizer

by TheAdviserMagazine
5 months ago
in Market Analysis
Reading Time: 5 mins read
A A
1 Stock to Buy, 1 Stock to Sell This Week: Meta Platforms, Pfizer
Share on FacebookShare on TwitterShare on LInkedIn


• Tariff headlines, ‘Mag 7’ earnings, U.S. jobs report, and PCE inflation data will be in focus this week.

• Meta is expected to report better-than-feared earnings due to an improving digital ad market, making it an appealing stock to buy.

• Pfizer’s expected earnings dive and sales decline suggest a more cautious approach.

• Looking for more actionable trade ideas? Subscribe here for 50% off InvestingPro!

The stock market ended higher on Friday, with the major averages registering sharp gains for the week driven by hopes for a de-escalation of the U.S.- China trade war.

The rose 2.5% for the week, the jumped 4.6%, while the tech-heavy soared 6.7%.

Source: Investing.com

More volatility could be in store this week as investors continue to assess the outlook for the economy, inflation, interest rates and corporate earnings amid President Donald Trump’s trade war.

Wall Street’s first quarter earnings season hits full swing, with four of the massive ‘Magnificent Seven’ tech stocks set to report their latest results. Microsoft (NASDAQ:) and Meta Platforms (NASDAQ:) report on Wednesday night, while Apple (NASDAQ:) and Amazon (NASDAQ:) are due late Thursday.

Other high-profile companies on the agenda include Qualcomm (NASDAQ:), ExxonMobil (NYSE:), Chevron (NYSE:), Eli Lilly (NYSE:), Pfizer (NYSE:), Coca-Cola (NYSE:), McDonald’s (NYSE:), Starbucks (NASDAQ:), United Parcel Service (NYSE:), Caterpillar (NYSE:), Robinhood (NASDAQ:), PayPal (NASDAQ:), Visa (NYSE:), and Mastercard (NYSE:).

Meanwhile, most important on the economic calendar will be Friday’s U.S. employment report, which is forecast to show the economy added 129,000 positions in April. The unemployment rate is seen holding steady at 4.2%.

Source: Investing.com

Besides the monthly jobs report, there is also important first-quarter GDP data, as well as the core PCE price index, which is the Fed’s favorite inflation gauge.

Regardless of which direction the market goes, below I highlight one stock likely to be in demand and another which could see fresh downside. Remember though, my timeframe is just for the week ahead, Monday, April 28 – Friday, May 2.

Stock To Buy: Meta Platforms

Meta Platforms looks positioned for a strong showing when it reports Q1 earnings this Wednesday after the close at 4:40PM ET. CEO Mark Zuckerberg and CFO Susan Li are scheduled to discuss the results during a 5:00PM ET earnings call.

The improving digital advertising market, coupled with Meta’s ongoing investments in AI and its massive user base across platforms like Facebook, Instagram, Threads, Reels, and WhatsApp, suggest the social media giant may deliver results that exceed tempered expectations.

Market participants foresee a sizable swing in META stock after the print drops, with a possible implied move of 8.3% in either direction.

Source: InvestingPro

While Meta’s growth has decelerated in recent quarters, analysts project a solid 13% year-over-year revenue increase to $41.3 billion, accompanied by an 11% rise in adjusted earnings per share to $5.20.

Despite broader market volatility and concerns over reduced ad spend from Chinese e-commerce firms due to escalating U.S.-China trade tensions, Meta’s diversified revenue streams and expanding global user base provide a buffer.

Moreover, Meta’s strategic investments in artificial intelligence, including new state-of-the-art data centers, position it well for long-term growth.

It is also worth noting that Meta will hold its initial ‘LlamaCon’ event on Tuesday, at which it is expected to highlight open-source advancements through its Llama family of generative AI models.

Source: Investing.com

META stock ended Friday’s session at $547.27, about 26% below its all-time high reached in mid-February. At current levels, the Menlo Park, California-based tech behemoth has a market cap of $1.38 trillion, making it the sixth most valuable company on the U.S. stock exchange.

As InvestingPro points out, Meta boasts a “GREAT” Financial Health Overall Score of 3.22, with particularly strong metrics in Profit (4.49) and Cash Flow (3.74). Analysts are overwhelmingly bullish on Meta, with a Strong Buy consensus recommendation (1.48) and a mean price target of $713.63, suggesting upside potential of 30.4% from current levels.

Be sure to check out InvestingPro to stay in sync with the market trend and what it means for your trading. Subscribe now and position your portfolio one step ahead of everyone else!

Stock to Sell: Pfizer

On the opposite end of the spectrum, Pfizer, the pharmaceutical giant, is bracing for the release of its Q1 financial results on Tuesday at 6:45AM ET. The ‘Big Pharma’ company is grappling with several headwinds, including declining demand for its COVID-19 products and increased competition in its non-COVID portfolio.

Additionally, Pfizer’s recent decision to abandon another obesity drug development program underscores the challenges it faces in replenishing its product pipeline and sustaining long-term growth.

Market participants expect a possible implied move of 4% in either direction in PFE stock after the print drops.

Source: InvestingPro

Analysts project a significant drop in earnings, with EPS expected to fall over 18% to $0.69 per share, and revenue anticipated to decrease by approximately 6% to $14.1 billion.

This pessimistic outlook is largely due to the expiration of the Diovan patent, a reduction in Rasilez/Titrandet demand, and increased competition in the ALTITUDE clinical study.

With limited near-term catalysts to offset these pressures, Pfizer’s stock could face further selling pressure post-earnings. While its dividend yield remains attractive at current price levels, Pfizer’s near-term growth prospects have dimmed considerably.

Source: Investing.com

PFE stock –which fell below $21 for the first time since July 2012 earlier this month– closed at $22.92 on Friday. At current valuations, Pfizer has a market cap of $130 billion. Shares, which are trading below their key moving averages, are down 13.6% in 2025.

As per InvestingPro, Pfizer maintains a “GOOD” Financial Health Overall Score of 2.86, with its strongest component being Profit (3.71), followed by Cash Flow (2.80) and Price Momentum (2.77). Growth is its weakest area at 2.03.

Whether you’re a novice investor or a seasoned trader, leveraging InvestingPro can unlock a world of investment opportunities while minimizing risks amid the challenging market backdrop.

Subscribe now and instantly unlock access to several market-beating features, including:

• ProPicks AI: AI-selected stock winners with proven track record.

• InvestingPro Fair Value: Instantly find out if a stock is underpriced or overvalued.

• Advanced Stock Screener: Search for the best stocks based on hundreds of selected filters, and criteria.

• Top Ideas: See what stocks billionaire investors such as Warren Buffett, Michael Burry, and George Soros are buying.

Disclosure: At the time of writing, I am long on the S&P 500, and the via the SPDR® S&P 500 ETF (SPY), and the Invesco QQQ Trust ETF (QQQ). I am also long on the Invesco Top QQQ ETF (QBIG), and Invesco S&P 500 Equal Weight ETF (RSP).

I regularly rebalance my portfolio of individual stocks and ETFs based on ongoing risk assessment of both the macroeconomic environment and companies’ financials.

The views discussed in this article are solely the opinion of the author and should not be taken as investment advice.

Follow Jesse Cohen on X/Twitter @JesseCohenInv for more stock market analysis and insight.



Source link

Tags: BuyMetaPfizerplatformsSellstockweek
ShareTweetShare
Previous Post

A Trump-induced interest rate cut won’t actually lower mortgage rates

Next Post

Regev seeks to connect Metro to Samaria

Related Posts

edit post
You Still Need A Design System — Now More Than Ever

You Still Need A Design System — Now More Than Ever

by TheAdviserMagazine
October 3, 2025
0

Design is in the news a lot these days. The US government recently created an initiative mandating better design for...

edit post
In The Age Of AI, Reinvention Is The Future Of Customer Success

In The Age Of AI, Reinvention Is The Future Of Customer Success

by TheAdviserMagazine
October 3, 2025
0

Picture it: New York City, September 2025, NY Customer Success Week.  A room full of over 700 CS practitioners gathered...

edit post
What Q2 2025 Technology Services Earnings Mean For Technology Executives

What Q2 2025 Technology Services Earnings Mean For Technology Executives

by TheAdviserMagazine
October 3, 2025
0

2025 has been a volatile year for technology service providers, with Q2 earnings revealing a landscape marked by mixed results...

edit post
Global Cybersecurity Spending To Exceed 0B By 2029

Global Cybersecurity Spending To Exceed $300B By 2029

by TheAdviserMagazine
October 3, 2025
0

Despite the ongoing macroeconomic uncertainty in 2025 fueled in part by sudden changes in US trade policy and tariffs, demand...

edit post
Why Accurate Surgical Procedure Data Is a Strategic Advantage Today?

Why Accurate Surgical Procedure Data Is a Strategic Advantage Today?

by TheAdviserMagazine
October 3, 2025
0

The global healthcare ecosystem is evolving rapidly, with surgical volumes serving as a crucial indicator of infrastructure readiness, patient demand,...

edit post
Bitcoin Rally Gains Steam as Key Resistance Zone Near 5,500 Comes Into View

Bitcoin Rally Gains Steam as Key Resistance Zone Near $125,500 Comes Into View

by TheAdviserMagazine
October 3, 2025
0

Bitcoin broke above $120,000 this week, gaining 7% and ending its bearish trading phase. Heavy inflows into spot ETFs and...

Next Post
edit post
Regev seeks to connect Metro to Samaria

Regev seeks to connect Metro to Samaria

edit post
Top Wall Street analysts pick these stocks for robust growth potential

Top Wall Street analysts pick these stocks for robust growth potential

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
California May Reimplement Mask Mandates

California May Reimplement Mask Mandates

September 5, 2025
edit post
Does a Will Need to Be Notarized in North Carolina?

Does a Will Need to Be Notarized in North Carolina?

September 8, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

September 9, 2025
edit post
Tips to Apply for Mental Health SSDI Without Therapy

Tips to Apply for Mental Health SSDI Without Therapy

September 19, 2025
edit post
Lamb Weston (LW) Q1 2026 Earnings: Key financials and quarterly highlights

Lamb Weston (LW) Q1 2026 Earnings: Key financials and quarterly highlights

0
edit post
I went to a day trading meetup and spoke to people with dreams of getting good enough to quit their 9-to-5

I went to a day trading meetup and spoke to people with dreams of getting good enough to quit their 9-to-5

0
edit post
The all-new Engagements is here. Get ready to win more business.

The all-new Engagements is here. Get ready to win more business.

0
edit post
Book Review: The Enduring Value of Roger Murray

Book Review: The Enduring Value of Roger Murray

0
edit post
The Financial Glow Up with Taylor Price

The Financial Glow Up with Taylor Price

0
edit post
OpenAI and Jony Ive may be struggling to figure out their AI device

OpenAI and Jony Ive may be struggling to figure out their AI device

0
edit post
I went to a day trading meetup and spoke to people with dreams of getting good enough to quit their 9-to-5

I went to a day trading meetup and spoke to people with dreams of getting good enough to quit their 9-to-5

October 5, 2025
edit post
OpenAI and Jony Ive may be struggling to figure out their AI device

OpenAI and Jony Ive may be struggling to figure out their AI device

October 5, 2025
edit post
Layoffs will start if shutdown talks ‘going nowhere’, says White House

Layoffs will start if shutdown talks ‘going nowhere’, says White House

October 5, 2025
edit post
FTX Issues Warning As Fraudulent Emails Circulate During .6B Creditor Payout

FTX Issues Warning As Fraudulent Emails Circulate During $1.6B Creditor Payout

October 5, 2025
edit post
Kalshi now sees government shutdown lasting nearly 21 days, second-longest in U.S. history

Kalshi now sees government shutdown lasting nearly 21 days, second-longest in U.S. history

October 5, 2025
edit post
Top Wall Street analysts recommend these 3 dividend stocks for stable returns

Top Wall Street analysts recommend these 3 dividend stocks for stable returns

October 5, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • I went to a day trading meetup and spoke to people with dreams of getting good enough to quit their 9-to-5
  • OpenAI and Jony Ive may be struggling to figure out their AI device
  • Layoffs will start if shutdown talks ‘going nowhere’, says White House
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.